Stage 0/I colon local treatment review Confirm endoscopic/pathological features and definitive local management. | care_pathway Guideline/evidence discussion; institutional protocol and current-label review required. | NCI-COLON |
Stage II colon observation discussion Routine adjuvant chemotherapy is not recommended in the absence of a high-risk subgroup. | care_pathway Guideline/evidence discussion; institutional protocol and current-label review required. | NCI-COLON, pdq_colon |
Stage II colon adjuvant risk/benefit review Discuss adjuvant treatment; T4 and other high-risk findings have different recommendation strength. | conventional_therapy Guideline/evidence discussion; institutional protocol and current-label review required. | NCI-COLON, pdq_colon, FDA-DPD, FDA-XELODA-2025, xeloda |
Stage II dMMR colon specialist review Do not routinely offer adjuvant chemotherapy solely because stage II disease is present; high-risk cases require individual review. | care_pathway Guideline/evidence discussion; institutional protocol and current-label review required. | NCI-COLON, pdq_colon |
Stage III colon FOLFOX / CAPOX review Discuss oxaliplatin plus fluoropyrimidine adjuvant therapy following resection. | conventional_therapy Guideline/evidence discussion; institutional protocol and current-label review required. | FDA-DPD, FDA-XELODA-2025, LABEL-OXALIPLATIN, NCI-COLON, pdq_colon, pm_29590544, pm_29611518, oxaliplatin |
Stage 0/I rectal local treatment review Determine whether local excision or oncologic resection is appropriate. | care_pathway Guideline/evidence discussion; institutional protocol and current-label review required. | NCI-RECTAL |
Locally advanced rectal total neoadjuvant therapy review Discuss total neoadjuvant therapy (induction vs consolidation chemotherapy; long-course CRT vs short-course RT) before restaging and local management. | conventional_therapy NCI PDQ and prospective randomized trials (OPRA, RAPIDO, UNICANCER-PRODIGE 23); institutional protocol and current component-label review required. | NCI-RECTAL, pdq_rectal, pm_35483010, pm_37883738, pm_33301740, pm_33862000, FDA-DPD, FDA-XELODA-2025 |
Lower-risk locally advanced rectal selective-radiation discussion In cT2N+, cT3N-, or cT3N+ sphincter-sparing candidates, neoadjuvant FOLFOX with selective pelvic chemoradiotherapy (reserved for <20% primary tumor decrease or FOLFOX intolerance) was noninferior to preoperative CRT for 5-year DFS (80.8% vs 78.6%, HR 0.92). | care_pathway Prospective randomized phase 3 trial PROSPECT (NCT01515787; PMID 37272534) and NCI PDQ rectal treatment summary. | NCI-RECTAL, pdq_rectal, pm_37272534, FDA-DPD, LABEL-OXALIPLATIN |
Dostarlimab (JEMPERLI) for MSI-H or dMMR stage II/III locally advanced rectal cancer Discuss single-agent dostarlimab (JEMPERLI §1.2) with the rectal multidisciplinary team. | biomarker_selected_therapy Rectal multidisciplinary team discussion. | LABEL-JEMPERLI-2026-10, pdq_rectal |
Rectal complete-response organ-preservation discussion Watch-and-wait organ preservation discussion for clinical complete response or near-complete response after TNT under structured endoscopic, DRE, and pelvic MRI surveillance, with salvage TME for local regrowth (5-yr DFS after TME at restaging vs TME at regrowth 64% vs 64% in OPRA). | care_pathway Prospective phase 2 OPRA trial (NCT02008656; PMID 35483010, PMID 37883738) and NCI PDQ rectal treatment summary. | NCI-RECTAL, pdq_rectal, pm_35483010, pm_37883738 |
Potentially curable metastatic local-treatment review Multidisciplinary hepatobiliary/thoracic surgical and local-therapy review at baseline and restaging (~2-month intervals during conversion systemic therapy to limit chemotherapy-associated steatohepatitis/sinusoidal injury). | care_pathway Guideline/evidence discussion; institutional protocol and current-label review required. | NCI-COLON, pdq_colon, pdq_rectal |
Pembrolizumab first-line review Selected molecular and treatment-setting conditions match the approval context. | biomarker_selected_therapy FDA CRC first-line approval; complete current label review required. | FDA-PD1 |
Nivolumab + ipilimumab review Selected MSI-H/dMMR metastatic conditions match the approval context; trial evidence is immunotherapy-naive. | biomarker_selected_therapy FDA 2025 CRC approval; software scope is adult metastatic, immunotherapy-naive discussion. | FDA-NIVO-IPI, opdivo |
FOLFOX / FOLFIRI + anti-VEGF review Discuss a chemotherapy doublet strategy with anti-VEGF treatment where appropriate. | conventional_therapy Guideline/evidence discussion; institutional protocol and current-label review required. | NCI-COLON, pdq_colon, avastin, FDA-DPD, FDA-XELODA-2025, LABEL-BEVACIZUMAB, LABEL-IRINOTECAN, LABEL-OXALIPLATIN |
Left-sided RAS/BRAF-wild-type doublet + anti-EGFR review The first-line anti-EGFR discussion is restricted to reviewed RAS wild type and left-sided primary. This preferred anti-EGFR doublet pathway requires both RAS and BRAF wild type; this does not exclude cetuximab within BRAF-targeted combinations. | biomarker_selected_therapy Guideline/evidence discussion; institutional protocol and current-label review required. | NCI-COLON, pdq_colon, erbitux, vectibix, pm_35666229, FDA-DPD, FDA-XELODA-2025, LABEL-IRINOTECAN |
Encorafenib + cetuximab + fluorouracil-based chemotherapy review The 2026 approval includes fluorouracil-based chemotherapy; BREAKWATER studied treatment-naive disease. | biomarker_selected_therapy FDA traditional approval February 24, 2026: adult BRAF V600E mCRC with cetuximab and fluorouracil-based chemotherapy; no treatment-naive restriction in section 1.2. Evidence population applicability is reported separately. | FDA-BRAF-2026, FDA-DPD, FDA-XELODA-2025, LABEL-BRAFTOVI-2026, LABEL-IRINOTECAN, LABEL-OXALIPLATIN |
Encorafenib + cetuximab after prior therapy FDA section 1.2 separately indicates encorafenib plus cetuximab after prior therapy for BRAF V600E metastatic CRC. | biomarker_selected_therapy FDA indication after prior therapy; distinct from the chemotherapy-containing regimen and its BREAKWATER population. | FDA-BRAF-2026, FDA-DPD, LABEL-BRAFTOVI-2026 |
Tucatinib + trastuzumab review Review after progression following the three specified chemotherapy backbones. | biomarker_selected_therapy FDA accelerated approval; confirm current status and full labels. | FDA-HER2, LABEL-TUKYSA-2026-10 |
Sotorasib + panitumumab review Specified prior chemotherapy and exact KRAS variant are required. | biomarker_selected_therapy FDA sotorasib plus panitumumab approval for adult KRAS G12C metastatic CRC after the specified prior chemotherapy. The indication does not explicitly require progression; prior therapy alone does not establish progression. This option does not inherit the separate adagrasib plus cetuximab CRC regulatory status. | FDA-KRAS-SOTO |
Adagrasib + cetuximab — historical CRC indication Historical CRC trial and approval criteria are retained for traceability. They do not establish current approval or eligibility. | biomarker_selected_therapy No current FDA approval in colorectal cancer. Current KRAZATI label (SPL version 14, effective 2026-08-31), Recent Major Changes: “KRAS G12C Mutated Locally Advanced or Metastatic Colorectal Cancer - Accelerated Approval Indication Removed 08/2026”; its only indication is KRAS G12C-mutated non-small cell lung cancer (§1). FDA lists the withdrawal on September 1, 2026. Historical criteria and KRYSTAL-1 results are kept as study evidence only. | FDA-KRAS-ADA, FDA-KRAS-ADA-WITHDRAWAL, LABEL-KRAZATI-2026-08, LABEL-KRAZATI-SPL-14 |
Trifluridine/tipiracil + bevacizumab review Prior exposure requirements include anti-EGFR when RAS wild type. | conventional_therapy FDA approved combination; exact full-label eligibility and safety review required. | FDA-FTD-BEV, LABEL-BEVACIZUMAB |
Fruquintinib review Anti-EGFR exposure is required for RAS wild type when medically appropriate. | conventional_therapy FDA approved refractory metastatic CRC context. | FDA-FRUQ |
CRC surveillance and survivorship review Review an individualized post-treatment surveillance plan. | care_pathway Guideline/evidence discussion; institutional protocol and current-label review required. | NCI-COLON, NCI-RECTAL |
FOLFOXIRI + bevacizumab first-line triplet review (TRIBE / TRIBE2) Higher response rate and longer PFS/OS vs FOLFIRI + bevacizumab in TRIBE (ECOG 0-2 age 18-70 or ECOG 0 age 71-75). | conventional_therapy FDA first-line fluoropyrimidine-irinotecan/oxaliplatin + bevacizumab label coverage; triplet studied in TRIBE/TRIBE2. | pm_25337750, pm_32164906, avastin, oxaliplatin, camptosar, FDA-DPD |
Capecitabine (XELODA) monotherapy first-line review Oral fluoropyrimidine option when combination chemotherapy is not preferred. | conventional_therapy FDA-approved single-agent mCRC indication when fluoropyrimidine therapy alone is preferred (XELODA section 1.1). | xeloda |
Capecitabine + bevacizumab first-line low-intensity review (AVEX) Prolonged PFS vs capecitabine alone in older patients unsuitable for oxaliplatin/irinotecan doublets (AVEX). | conventional_therapy Prospective phase 3 trial support (AVEX, age >=70 not candidates for oxaliplatin/irinotecan); AVASTIN section 1.1 names intravenous fluorouracil-based chemotherapy (clinician review required for oral capecitabine pairing). | pm_24028813, xeloda, avastin |
Fluoropyrimidine + bevacizumab maintenance / oxaliplatin stop-and-go review (CAIRO3 / OPTIMOX1) Maintains disease control after induction while pausing oxaliplatin cumulative sensory neuropathy. | conventional_therapy Prospective phase 3 maintenance/de-escalation trials after non-progressing oxaliplatin induction (CAIRO3, OPTIMOX1). | pm_25862517, pm_16421419, xeloda, avastin, FDA-DPD |
Second-line switched doublet (FOLFOX or FOLFIRI) + bevacizumab review (ML18147 / E3200) Overall survival and PFS improvement over switched chemotherapy alone in ML18147 and E3200. | conventional_therapy FDA-approved second-line mCRC with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin after progression on first-line bevacizumab-containing regimen (ML18147) or without prior bevacizumab (E3200). | avastin, oxaliplatin, camptosar, FDA-DPD |
Ziv-aflibercept (ZALTRAP) + FOLFIRI second-line review (VELOUR) Improved OS, PFS, and ORR vs placebo + FOLFIRI in VELOUR (with or without prior bevacizumab). | conventional_therapy FDA-approved in combination with FOLFIRI for mCRC resistant to or progressed following an oxaliplatin-containing regimen (ZALTRAP section 1). | zaltrap, camptosar, FDA-DPD |
Ramucirumab (CYRAMZA) + FOLFIRI second-line review (RAISE) Improved OS and PFS vs placebo + FOLFIRI in RAISE. | conventional_therapy FDA-approved in combination with FOLFIRI for mCRC with progression on or after prior bevacizumab, oxaliplatin, and a fluoropyrimidine (CYRAMZA section 1.3). | cyramza, camptosar, FDA-DPD |
Second-line switched chemotherapy without anti-angiogenic (FOLFIRI, FOLFOX, or irinotecan) Cytotoxic backbone switch when anti-angiogenic therapy is contraindicated. | conventional_therapy FDA-approved irinotecan/5-FU/LV or oxaliplatin/5-FU/LV backbones when anti-VEGF/anti-EGFR agents are contraindicated or omitted. | camptosar, oxaliplatin, FDA-DPD, pdq_colon |
Regorafenib (STIVARGA) monotherapy in refractory mCRC (CORRECT) Statistically significant OS and PFS prolongation over placebo + BSC in CORRECT. | conventional_therapy FDA-approved for mCRC previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy (STIVARGA section 1.1). | stivarga |
Anti-EGFR therapy (cetuximab +/- irinotecan, or panitumumab) in anti-EGFR-naive RAS/BRAF-WT mCRC Improved OS/PFS vs BSC in RAS/KRAS wild-type refractory mCRC (CA225-025, 20020408, 20100007, 20080763) and higher ORR with cetuximab + irinotecan vs cetuximab alone (BOND). | biomarker_selected_therapy FDA-approved cetuximab (with irinotecan after irinotecan-based therapy or single-agent after irinotecan and oxaliplatin) and panitumumab monotherapy after fluoropyrimidine, oxaliplatin, and irinotecan in RAS wild-type mCRC. | erbitux, vectibix, camptosar |
ctDNA-guided anti-EGFR rechallenge discussion in RAS/BRAF-WT mCRC (CRICKET / CHRONOS) Objective responses observed in prospective phase 2 rechallenge cohorts lacking acquired RAS/BRAF/EGFR resistance mutations in plasma ctDNA. | biomarker_selected_therapy Off-label rechallenge strategy supported by prospective phase 2 trials CRICKET (cetuximab + irinotecan) and CHRONOS (ctDNA-selected panitumumab); clinician sign-off pending. | pm_30476968, pm_35915157, erbitux, vectibix, camptosar |